Quick Answer
Nasus Pharma Ltd reported Cash and Equivalents of $1.24 million for fiscal year 2025.
Nasus Pharma Ltd Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $1.24M | +335.6% |
| 2024 | $284.0K | +47.2% |
| 2023 | $193.0K | — |
- Nasus Pharma Ltd showed an increase of +335.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, Nasus Pharma Ltd’s cash and equivalents has grown by 540.9% (from $193.0 thousand to $1.24 million).
- The most recent figure is from Nasus Pharma Ltd’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: